Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ITCC-P4

Financiado

Cerrado

ITCC Pediatric Preclinical POC Platform Sofia ref. 116064

Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options a... ver más

31/12/2023

GERMAN CANCER RESE...

20M€

Presupuesto del proyecto: 20M€

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 34 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

IMI2-2015-07-05: A COMPREHENSIVE ‘PAEDIATRIC PRECLIN...

I+D

Cerrada hace 8 años

0% 37% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

34 Participantes

GERMAN CANCER RESEARCH CENTE...

1.73M€ | Lider

CAF RAIL DIGITAL SERVICES SL

271.14K€ | Participante

EGILE MECHANICS

190.51K€ | Participante

JANSSEN PHARMACEUTICA NV

66.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Decode Relapse Decoding and Targeting Treatment-Resistant Metastatic Neurob... 2M€ Cerrado

PID2019-111256RB-I00 TERAPIA ANTITUMORAL ADAPTATIVA USANDO DATOS TRANSVERSALES Y... 72K€ Cerrado

SENCAN Senescence therapy for cancer 2M€ Cerrado

RESISTANCEPROGRAMS Tumor recurrence and therapeutic resistance: exploring and e... 2M€ Cerrado

SAF2015-74072-JIN DRIVERMAP: ESTIMANDO LA RELEVANCIA DE LAS MUTACIONES ONCOGEN... 205K€ Cerrado

CanSel Highly selective customizable therapy for metastatic tumors 166K€ Cerrado

Duración del proyecto: 79 meses Fecha Inicio: 2017-05-18
Fecha Fin: 2023-12-31

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 20M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs. To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores